Teleflex Announces New Initiatives to Uphold Medical Technologies
WAYNE, Pa. (Date) - Teleflex Incorporated, a global leader in medical technologies, has recently unveiled several groundbreaking advancements in the healthcare industry. The company announced the establishment of the Teleflex Center for Antimicrobial Protection (TCAP) as a strategic branch of its Vascular Access business unit. In addition, Teleflex has also introduced the limited market release of the Wattson Temporary Pacing Guidewire and the upcoming full market release of the UroLift 2 System with Advanced Tissue Control. These innovative developments mark significant advancements in their respective fields and demonstrate Teleflex’s commitment to improving patient care.
The Teleflex Center for Antimicrobial Protection (TCAP) aims to address the growing concern of healthcare-associated infections. Led by Chuck Gartner, the Director of Marketing - Strategic Initiatives at Teleflex’s Vascular Access business unit, TCAP will focus on developing antimicrobial solutions and technologies to enhance the safety and efficacy of medical procedures. By integrating antimicrobial properties into medical devices, Teleflex aims to reduce the risk of infection transmission, ultimately improving patient outcomes.
In an effort to expand its structural heart portfolio, Teleflex has introduced the Wattson Temporary Pacing Guidewire. This device plays a crucial role in cardiac catheterization procedures by facilitating the introduction and positioning of catheters and other interventional devices within the heart chambers. By transmitting electrical signals from an external pulse generator to the heart, the temporary pacing guidewire enables precise control and monitoring during procedures. This innovative technology enhances the accuracy and effectiveness of cardiac interventions, benefiting both patients and healthcare professionals.
Teleflex’s commitment to improving the treatment of benign prostatic hyperplasia (BPH) has resulted in the development of the UroLift 2 System with Advanced Tissue Control (UroLift 2 ATC). This unified platform is designed to treat BPH symptoms in men with all prostate types up to 100g. With the Advanced Tissue Control feature, which has received FDA clearance, the UroLift 2 ATC offers enhanced precision and control during the procedure. This advancement represents a significant improvement in BPH care, providing a safer and more effective treatment option for patients and physicians alike.
With these recent advancements, Teleflex has solidified its position as an industry leader in medical technologies. The establishment of the Teleflex Center for Antimicrobial Protection and the introduction of the Wattson Temporary Pacing Guidewire and UroLift 2 System with Advanced Tissue Control showcase the company’s commitment to innovation and improving patient outcomes. Healthcare professionals and patients can look forward to these groundbreaking technologies and the positive impact they will have on medical procedures and patient care.
Comments